141 related articles for article (PubMed ID: 37370943)
1. Dynamic and Static
Wumener X; Ye X; Zhang Y; Jin S; Liang Y
Diagnostics (Basel); 2023 Jun; 13(12):. PubMed ID: 37370943
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Dynamic FDG-PET imaging for differentiating metastatic from non-metastatic lymph nodes of lung cancer.
Wumener X; Zhang Y; Wang Z; Zhang M; Zang Z; Huang B; Liu M; Huang S; Huang Y; Wang P; Liang Y; Sun T
Front Oncol; 2022; 12():1005924. PubMed ID: 36439506
[TBL] [Abstract][Full Text] [Related]
4. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
Ann Nucl Med; 2009 Aug; 23(6):523-31. PubMed ID: 19444550
[TBL] [Abstract][Full Text] [Related]
5. F-18-FDG-avid lymph node metastasis along preferential lymphatic drainage pathways from the tumor-bearing lung lobe on F-18-FDG PET/CT in patients with non-small-cell lung cancer.
Shigemoto Y; Suga K; Matsunaga N
Ann Nucl Med; 2016 May; 30(4):287-97. PubMed ID: 27007128
[TBL] [Abstract][Full Text] [Related]
6. Higher accuracy of [
Zhou X; Wang S; Xu X; Meng X; Zhang H; Zhang A; Song Y; Zhu H; Yang Z; Li N
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2983-2993. PubMed ID: 35543731
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic ability of
Lee JW; Kim EY; Kim DJ; Lee JH; Kang WJ; Lee JD; Yun M
Eur Radiol; 2016 Dec; 26(12):4515-4523. PubMed ID: 26943133
[TBL] [Abstract][Full Text] [Related]
8. Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer.
Cuaron J; Dunphy M; Rimner A
Front Oncol; 2012; 2():208. PubMed ID: 23316478
[TBL] [Abstract][Full Text] [Related]
9. SMARCA4-deficient thoracic tumor detected by [
Okazaki T; Yokoyama K; Tsuchiya J; Honda T; Ishikawa Y; Kirimura S; Miyazaki Y; Tateishi U
Eur J Hybrid Imaging; 2021 Apr; 5(1):8. PubMed ID: 34181162
[TBL] [Abstract][Full Text] [Related]
10. Impact of
Al-Ibraheem A; Hirmas N; Fanti S; Paez D; Abuhijla F; Al-Rimawi D; Al-Rasheed U; Abdeljalil R; Hawari F; Alrabi K; Mansour A
BMC Med Imaging; 2021 Mar; 21(1):49. PubMed ID: 33731050
[TBL] [Abstract][Full Text] [Related]
11. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.
Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
Ann Nucl Med; 2009 Jul; 23(5):427-35. PubMed ID: 19437097
[TBL] [Abstract][Full Text] [Related]
12. Impact of EBUS-TBNA in addition to [
Guberina M; Darwiche K; Hautzel H; Ploenes T; Pöttgen C; Guberina N; Herrmann K; Umutlu L; Wetter A; Theegarten D; Aigner C; Eberhardt WEE; Schuler M; Karpf-Wissel R; Stuschke M
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2894-2903. PubMed ID: 33547554
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous uptake of
Hu Y; Wang P; Dai W
BMC Pulm Med; 2023 Mar; 23(1):73. PubMed ID: 36882747
[TBL] [Abstract][Full Text] [Related]
14. Combined use of (18)F-FDG and (18)F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study.
Sachpekidis C; Thieke C; Askoxylakis V; Nicolay NH; Huber PE; Thomas M; Dimitrakopoulou G; Debus J; Haberkorn U; Dimitrakopoulou-Strauss A
Am J Nucl Med Mol Imaging; 2015; 5(2):127-42. PubMed ID: 25973334
[TBL] [Abstract][Full Text] [Related]
15. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of virtual 18F-FDG PET/CT bronchoscopy for the detection of lymph node metastases in non-small cell lung cancer patients.
Herbrik M; Treffert J; Geiger B; Riegger C; Hartung V; Rosenbaum-Krumme SJ; Forsting M; Antoch G; Heusner TA
J Nucl Med; 2011 Oct; 52(10):1520-5. PubMed ID: 21908390
[TBL] [Abstract][Full Text] [Related]
17. [Significance of dual-time-point 18F-FDG PET imaging in evaluation of hilar and mediastinal lymph node metastasis in non-small-cell lung cancer].
Hu M; Yu JM; Liu NB; Liu LP; Guo HB; Yang GR; Zhang PL; Xu XQ
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):306-9. PubMed ID: 18788639
[TBL] [Abstract][Full Text] [Related]
18. Comparison of
Wu J; Deng H; Zhong H; Wang T; Rao Z; Wang Y; Chen Y; Zhang C
Front Oncol; 2022; 12():924223. PubMed ID: 35860594
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
[TBL] [Abstract][Full Text] [Related]
20. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
